SURF Stock Overview
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States.
+ 1 more risk
Surface Oncology Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.74|
|52 Week High||US$8.38|
|52 Week Low||US$1.37|
|1 Month Change||-8.90%|
|3 Month Change||-38.30%|
|1 Year Change||-76.52%|
|3 Year Change||-31.23%|
|5 Year Change||n/a|
|Change since IPO||-86.95%|
Recent News & Updates
Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline
Surface Oncology has been a major drag for investors. There's no bad news, but there's no good news either. Despite having partnerships with big names, the stock does not move up.
News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts
Surface Oncology, Inc. ( NASDAQ:SURF ) shareholders will have a reason to smile today, with the analysts making...
|SURF||US Biotechs||US Market|
Return vs Industry: SURF underperformed the US Biotechs industry which returned -24.5% over the past year.
Return vs Market: SURF underperformed the US Market which returned -18.8% over the past year.
|SURF Average Weekly Movement||12.7%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: SURF is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: SURF's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No.
Surface Oncology Fundamentals Summary
|SURF fundamental statistics|
Is SURF overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SURF income statement (TTM)|
|Cost of Revenue||US$59.65m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.04|
|Net Profit Margin||-182.62%|
How did SURF perform over the long term?See historical performance and comparison
Is SURF undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SURF?
Other financial metrics that can be useful for relative valuation.
|What is SURF's n/a Ratio?|
Price to Sales Ratio vs Peers
How does SURF's PS Ratio compare to its peers?
|SURF PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
FBIO Fortress Biotech
HOOK HOOKIPA Pharma
DYAI Dyadic International
CRDF Cardiff Oncology
SURF Surface Oncology
Price-To-Sales vs Peers: SURF is good value based on its Price-To-Sales Ratio (3.1x) compared to the peer average (78.8x).
Price to Earnings Ratio vs Industry
How does SURF's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: SURF is good value based on its Price-To-Sales Ratio (3.1x) compared to the US Biotechs industry average (13.7x)
Price to Sales Ratio vs Fair Ratio
What is SURF's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||3.1x|
|Fair PS Ratio||2x|
Price-To-Sales vs Fair Ratio: SURF is expensive based on its Price-To-Sales Ratio (3.1x) compared to the estimated Fair Price-To-Sales Ratio (2x).
Share Price vs Fair Value
What is the Fair Price of SURF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SURF's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SURF's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SURF's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Surface Oncology forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SURF is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SURF is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SURF is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SURF's revenue (53.2% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: SURF's revenue (53.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SURF's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Surface Oncology performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SURF is currently unprofitable.
Growing Profit Margin: SURF is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SURF is unprofitable, but has reduced losses over the past 5 years at a rate of 9.8% per year.
Accelerating Growth: Unable to compare SURF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SURF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: SURF has a negative Return on Equity (-38.59%), as it is currently unprofitable.
Discover strong past performing companies
How is Surface Oncology's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SURF's short term assets ($184.3M) exceed its short term liabilities ($19.6M).
Long Term Liabilities: SURF's short term assets ($184.3M) exceed its long term liabilities ($51.1M).
Debt to Equity History and Analysis
Debt Level: SURF has more cash than its total debt.
Reducing Debt: Insufficient data to determine if SURF's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SURF has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SURF has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 12.9% each year.
Discover healthy companies
What is Surface Oncology current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SURF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SURF's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SURF's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SURF's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SURF has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rob Ross (47 yo)
Dr. Robert W. Ross, also known as Rob, M.D., is President, Chief Executive Officer and Director at Surface Oncology, Inc since April 01, 2021. He serves as Director at Xilio Therapeutics, Inc. since June 2...
CEO Compensation Analysis
Compensation vs Market: Rob's total compensation ($USD4.68M) is above average for companies of similar size in the US market ($USD752.76K).
Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.
Experienced Management: SURF's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: SURF's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.7%.
Surface Oncology, Inc.'s employee growth, exchange listings and data sources
- Name: Surface Oncology, Inc.
- Ticker: SURF
- Exchange: NasdaqGM
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$95.021m
- Shares outstanding: 54.61m
- Website: https://www.surfaceoncology.com
Number of Employees
- Surface Oncology, Inc.
- 50 Hampshire Street
- 8th Floor
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/28 00:00|
|End of Day Share Price||2022/06/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.